We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
No glucose readings will be displayed. Always charge immediately when the smart transmitter battery is completely drained. The system will return to Initialization phase if the battery is not charged within 16 hours of a Battery Empty alert.
The mobile app will also display a “No Transmitter Detected” status banner.
In the Eversense E3 pivotal clinical trial (PROMISE Study), the system required primarily 1 cal/day, prompting for a median of one-calibration per day 62% of the time, and two calibrations per day 38% of the time, after day 21.
The Eversense® NOW App is only intended for viewing glucose data.
The Eversense® E3 Sensor and adhesive patches contain silicone. If you have any concerns about allergic reaction to silicones, contact your health care professional prior to use.
Eversense® E3 Sensor is manufactured by Senseonics across the US and Europe.
Eversense® E3 Transmitter is manufactured by Senseonics in Minnesota, USA.
The Eversense® E3 Smart Transmitter can store up to one year of glucose data.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1